Compare ANGH & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGH | ALGS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 34.6M |
| IPO Year | 2021 | 2020 |
| Metric | ANGH | ALGS |
|---|---|---|
| Price | $3.40 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $52.38 |
| AVG Volume (30 Days) | 4.4K | ★ 37.9K |
| Earning Date | 04-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $251.30 | $1,562.10 |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.25 | $3.98 |
| 52 Week High | $7.89 | $13.69 |
| Indicator | ANGH | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 37.04 |
| Support Level | $3.09 | $4.97 |
| Resistance Level | $3.89 | $6.91 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 31.03 | 3.57 |
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.